Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

Blood (2018) 132 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2018-99-115132

Published: 2018

Journal Articles

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2018) 132 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2018-99-113411

Published: 2018

Journal Articles

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Blood (2018) 131 (24): 2661–2669.

https://doi.org/10.1182/blood-2017-12-818948

Published: 2018

Includes: Supplemental data

Journal Articles

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Neerav Shukla, MD, Cynthia Wetmore, MD PhD, Maureen M O'Brien, MD, Lewis B. Silverman, MD, Patrick Brown, MD, Todd M Cooper, DO, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Ben Suttle, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2016) 128 (22): 2780.

https://doi.org/10.1182/blood.V128.22.2780.2780

Published: 2016

Journal Articles

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Eytan M. Stein, MD, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Raoul Tibes, MD PhD, Jesus G. Berdeja, MD, Mojca Jongen-Lavrencic, MD PhD, Jessica K. Altman, MD, Hartmut Dohner, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Greg Fine, MS, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Bob Lowenberg, MD PhD, Martin S Tallman, MD

Blood (2015) 126 (23): 2547.

https://doi.org/10.1182/blood.V126.23.2547.2547

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Vincent Ribrag, Jean-Charles Soria, Professor, Jean-Marie Michot, Anna Schmitt, MD, Sophie Postel-Vinay, MD, Fontanet Bijou, MD, Blythe Thomson, MD, Heike Keilhack, PhD, Stephen J. Blakemore, PhD, Larisa Reyderman, PhD, Pavan Kumar, PhD, Greg Fine, MS, Alice McDonald, Peter T Ho, PhD MD, Antoine Italiano, MD

Blood (2015) 126 (23): 473.

https://doi.org/10.1182/blood.V126.23.473.473

Published: 2015

Journal Articles

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Blood (2014) 123 (5): 632–639.

https://doi.org/10.1182/blood-2013-05-504340

Published: 2014

Includes: Supplemental data

Journal Articles

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

Daniel J. DeAngelo, MD, Ph.D, Harry P Erba, MD, Michael B Maris, MD, Ronan T. Swords, MD, PhD, FRCPI, FRCPath, Faiz Anwer, MD, Jessica K Altman, MD, Zhaowei Hua, Ph.D, Stephen J Blakemore, Ph.D, Hélène Faessel, Ph.D, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2013) 122 (21): 1443.

https://doi.org/10.1182/blood.V122.21.1443.1443

Published: 2013

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

NARROW

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only